[HTML][HTML] Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas
Recent discoveries have provided valuable insight into the genomic landscape of pediatric
low-grade gliomas (LGGs) at diagnosis, facilitating molecularly targeted treatment. However, …
low-grade gliomas (LGGs) at diagnosis, facilitating molecularly targeted treatment. However, …
[PDF][PDF] Tumor response assessment in diffuse intrinsic pontine glioma: comparison of semiautomated volumetric, semiautomated linear, and manual linear tumor …
LA Gilligan, MD DeWire-Schottmiller… - American Journal …, 2020 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: 2D measurements of diffuse intrinsic pontine gliomas are
limited by variability, and volumetric response criteria are poorly defined. Semiautomated 2D …
limited by variability, and volumetric response criteria are poorly defined. Semiautomated 2D …
Trametinib-associated hyponatremia in a child with low-grade glioma is not seen following treatment with alternative MEK inhibitor
…, NP Smiley, MD DeWire-Schottmiller… - Journal of Pediatric …, 2021 - journals.lww.com
Molecularly targeted therapy with MEK inhibitors has been increasingly incorporated into
the treatment of pediatric low-grade gliomas, but this promising therapy is associated with …
the treatment of pediatric low-grade gliomas, but this promising therapy is associated with …
DIPG-46. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING …
…, C Fuller, A Lane, MD DeWire-Schottmiller… - Neuro …, 2020 - academic.oup.com
INTRODUCTION The role of diagnostic biopsy in diffuse intrinsic pontine glioma (DIPG)
remains in question. Distinguishing radiographically between DIPG and other pontine tumors …
remains in question. Distinguishing radiographically between DIPG and other pontine tumors …
MR imaging features of diffuse intrinsic pontine glioma and relationship to overall survival: report from the International DIPG Registry
…, R Doughman, R Drissi, M DeWire-Schottmiller… - Neuro …, 2020 - academic.oup.com
Background This study describes imaging features of diffuse intrinsic pontine glioma (DIPG)
and correlates with overall survival (OS) and histone mutation status in the International …
and correlates with overall survival (OS) and histone mutation status in the International …
LGG-31. CHARACTERIZING TEMPORAL GENOMIC HETEROGENEITY IN PEDIATRIC LOW GRADE GLIOMAS: ANALYSIS OF AN EXPANDED MULTI …
MA Lazow, A Schafer, MD DeWire-Schottmiller… - Neuro …, 2020 - academic.oup.com
INTRODUCTION Recent discoveries have provided valuable insight into the genomic
landscape of pediatric low grade gliomas (LGGs) at diagnosis, facilitating molecularly targeted …
landscape of pediatric low grade gliomas (LGGs) at diagnosis, facilitating molecularly targeted …
Phase 1 Safety Study of BXQ-350 in Children/Young Adults with Relapsed Solid Tumors, Including Malignant Brain Tumors
MS Abdelbaki, MD DeWire Schottmiller… - Young Adults with … - papers.ssrn.com
… Mariko Dawn DeWire Schottmiller … Richard Curry, MD has shares of Bexion amounting to
less than 1% ownership. All others have nothing to declare, … Mariko Dawn DeWire Schottmiller …
less than 1% ownership. All others have nothing to declare, … Mariko Dawn DeWire Schottmiller …
Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry
…, P Bandopadhayhay, M DeWire-Schottmiller… - Neuro …, 2022 - academic.oup.com
Background Cross-sectional tumor measures are traditional clinical trial endpoints; however
volumetric measures may better assess tumor growth. We determined the correlation and …
volumetric measures may better assess tumor growth. We determined the correlation and …
LGG-30. TRAMETINIB-ASSOCIATED HYPONATREMIA IN A CHILD WITH LOW GRADE GLIOMA IS NOT SEEN FOLLOWING TREATMENT WITH ALTERNATIVE MEK …
…, NP Smiley, MD DeWire-Schottmiller… - Neuro …, 2020 - ncbi.nlm.nih.gov
Molecularly targeted therapy with MEK inhibitors is increasingly being incorporated into the
treatment of pediatric low-grade gliomas (LGGs). Trametinib is an orally available MEK1/2 …
treatment of pediatric low-grade gliomas (LGGs). Trametinib is an orally available MEK1/2 …
Characteristics of children≤ 36 months of age with DIPG: A report from the international DIPG registry
…, R Packer, M Kieran, M DeWire-Schottmiller… - Neuro …, 2022 - academic.oup.com
Background Children ≤36 months with diffuse intrinsic pontine glioma (DIPG) have increased
long-term survival (LTS, overall survival (OS) ≥24 months). Understanding distinguishing …
long-term survival (LTS, overall survival (OS) ≥24 months). Understanding distinguishing …